CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results